TY -的T1 EMCOOLs表面冷却系统的性能对急性发热控制Neurocritical护理病人(P3.180) JF -神经学乔-神经学六世- 88 - 16补充SP - P3.180 AU -斯蒂芬·格里菲思盟-查尔斯Francoeur AU -埃罗尔·戈登盟Ne首页ha Dangayach AU -丹尼尔做非盟- Anil Ramineni盟Javaad Ahmad AU -斯蒂芬Mayer Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P3.180.abstract N2 -目的:评估EMCOOLs装置的冷却能力。背景:热发生在20 - 50%的重病神经病人,甚至小温度海拔与发病率增加。先进的治疗温度管理系统是资源密集型和并不总是容易获得,导致延误治疗。EMCOOLS垫是由多个冷却单元充满hypocarbon®,以胶下面,允许高效的传热。垫存储−10°C,并可以直接使用。设计/方法:EMCOOL设备包括所有科目的回顾性分析,该设备应用于神经重症监护病房(NSICU)与一致的温度数据记录。初步结果来自8个科目(平均年龄52.1±8.3,平均重量= 82.5±11.6),与诊断包括蛛网膜下腔出血(38%)、颅内出血(25%),硬膜下出血(13%)、精神状态改变(13%),良性肿瘤(13%)。所有受试者发热(≥38.0°C)在最初的应用程序中,100%的人服用一种药在2小时之前和/或治疗期间,无意识的在治疗期间的50%。床边发抖评估范围被记录。结果:主题显示一个线性1.4°C (T0avg = 38.9°C, T120avg = 37.7°C)温度下降在120分钟从最初的应用程序中,与正常体温(≤38.0°C)达到75分钟。Comapatients显示更高的冷却T120比醒着的主题(ΔTcoma = 1.9°C vsΔTawake = 0.9°C, P = 0.14)。 Of the total subjects, 25% had shivering events upon application (BSAS 2), which subsided after approximately 10 mins, 50% experienced no shivering, and 25% had no BSAS reported. No skin damage was observed upon removal of the device.Conclusions: Preliminary results show the EMCOOLS pads are effective and safe in controling temperature elevations in neurologically critically ill patients.Disclosure: Dr. Griffiths has nothing to disclose. Dr. Francoeur has nothing to disclose. Dr. Gordon has nothing to disclose. Dr. Dangayach has nothing to disclose. Dr. Wheelwright has nothing to disclose. Dr. Ramineni has nothing to disclose. Dr. Ahmad has nothing to disclose. Dr. Mayer has received personal compensation for activities with Bard Medical. ER -